Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On December 20, 2021, Coherus announced the FDA approval of Yusimry (adalimumab-aqvh), a biosimilar to AbbVie’s Humira® (adalimumab).
Download PDF
Return to publications
